FC26: When to Start, When to Switch: Positioning JAK Inhibitors in Atopic Dermatitis Management: An Online Activity

Start a JAK inhibitor? Switch to a JAK inhibitor? Discover a clear framework for safely positioning JAK inhibitors in atopic dermatitis care. In this session from the 2026 Fall Clinical Dermatology Conference®, our expert faculty panel uses clinical and real-world evidence to give learners guideposts for confident treatment decisions.
“I want to walk you through a really cool real-world study looking at upadacitinib and abrocitinib… What you're seeing here is nearly comparable efficacy in terms of skin clearance, itch relief and hitting minimal disease activity in the real world between upadacitinib and abrocitinib at two years. If we look at the safety over these two years, no new signals, nothing worrisome. What don't you see here? You don't see MACE, VTE, or malignancy.” – Christopher G. Bunick, MD, PhD
FC26: When to Start, When to Switch: Positioning JAK Inhibitors in Atopic Dermatitis Management: An Online Activity
This activity is supported by an educational grant from AbbVie.